Sobi Haemophilia

We are Sobi Haemophilia
Sobi Haemophilia is part of Sobi” Swedish Orphan Biovitrum AB”, a specialty pharmaceutical company based in Stockholm, Sweden. We have a history of innovation in haemophilia that stretches back more than 50 years. Today, we continue to build on that history through a global partnership with Biogen Idec, an American biotechnology company, to develop new treatments for haemophilia. We have a fresh approach to partnering with the haemophilia community – people with haemophilia, their families, the healthcare professionals that care for them and the organisations that represent them – and look forward to sharing this with you.

Our commitment to people with haemophilia

Sobi strives to understand the needs of people with haemophilia. We want to contribute to a world where people with haemophilia in every country are diagnosed at birth and receive effective treatment and life-long support – living a full life, free from the limitations of haemophilia.

Improving access to treatments

Modern treatments have the potential to transform the lives of people with haemophilia – but are not yet available to everyone who needs them. We want to help improve access to treatment for people with haemophilia, and to make access more equitable.

As a concrete example of this, Sobi and our partner Biogen are donating one billion units of clotting factor for humanitarian aid in developing countries over the next ten years. The first 500 million have already been earmarked for the World Federation of Haemophilia’s Humanitarian Aid Program, to help improve the standard of care for people with haemophilia in the developing world.

We have committed to donating up to 500 million International Units (IU) of haemophilia clotting factor over the next 5 years, and a further 500 million IU in the following years. Our large-volume manufacturing technology means that we are able to make treatment available at this scale.